Gastrointestinal stromal tumor - A review of clinical studies

Forskningsoutput: TidskriftsbidragÖversiktsartikel

Abstract

Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. With the advent of Imatinib, the treatment of gastrointestinal stromal tumor has been revolutionized as both the progression-free and overall survival rates have increased dramatically. Unfortunately, gastrointestinal stromal tumor patients on Imatinib do eventually fail due to resistance. Even though sunitinib and regorafenib have been shown to be highly effective as second- and third-line treatments, both have limited effects. New treatments are highly warranted for this reason. In this present review, 25 registered pharmacological clinical trials at ClinicalTrials.gov have been reviewed and show promising and encouraging results.

Detaljer

Författare
Enheter & grupper
Externa organisationer
  • Skåne University Hospital
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Cell- och molekylärbiologi
  • Farmakologi och toxikologi
  • Cancer och onkologi

Nyckelord

Originalspråkengelska
Sidor (från-till)1473–1485
TidskriftJournal of oncology pharmacy practice
Volym25
Utgåva nummer6
Tidigt onlinedatum2019 maj 8
StatusPublished - 2019
PublikationskategoriForskning
Peer review utfördJa